Heartbeam Inc Stock Price, News & Analysis

HeartBeam (NASDAQ: BEAT) reported Q2 2025 financial results and provided updates on its commercial readiness plans. The company's pivotal VALID-ECG study demonstrated 93.4% overall diagnostic agreement for its 12-lead ECG synthesis software. HeartBeam continues productive FDA discussions, expecting 510(k) clearance by year-end.

Financial highlights include $5.1 million in cash and equivalents, with Q2 net loss of $5.0 million. R&D expenses increased to $3.3 million from $2.8 million year-over-year, while G&A expenses decreased to $1.7 million from $2.2 million.

The company expanded its business development team and received two industry recognitions, including the Innovation Award in Remote Cardiac Diagnostics. HeartBeam's patent portfolio now includes 21 issued patents worldwide.

HeartBeam (NASDAQ: BEAT), a medical technology company specializing in cardiac care solutions, has scheduled its Q2 2025 earnings conference call for August 13, 2025, at 4:30 p.m. Eastern time. The call will be led by CEO Robert Eno and CFO Timothy Cruickshank, who will discuss second quarter results and provide updates on regulatory initiatives and commercial activities.

The earnings release will be issued before the call, which will include a presentation accessible through the company's investor relations website. Participants can join via phone using U.S. dial-in 1-844-826-3035 or international dial-in 1-412-317-5195 with conference code 10201583. A webcast will also be available, and a replay will be accessible until November 13, 2025.

HeartBeam (NASDAQ: BEAT) has been awarded the Innovation Award in Remote Cardiac Diagnostics at the 2025 Medical Device Network Excellence Awards for its groundbreaking FDA-cleared ECG technology. The company's proprietary technology captures heart electrical signals in 3D non-coplanar directions and synthesizes them into a 12-lead ECG using a credit card-sized, cable-free device.

The technology enables clinical-grade diagnostics for arrhythmia assessment outside traditional healthcare settings, allowing patients to record symptoms as they occur. HeartBeam's 12-lead ECG synthesis software is currently under FDA review, with commercialization planned upon clearance. The company has previously received multiple industry recognitions, including the Pinnacle Healthcare Award and MedTech Breakthrough Award.

HeartBeam (NASDAQ: BEAT), a cardiac care medical technology company, announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Summer Conference. CEO Robert Eno and CFO Timothy Cruickshank will deliver a presentation on June 24, 2025, at 2:00 p.m. Eastern Time. The virtual event, scheduled for June 24-25, 2025, will include one-on-one meetings with institutional investors. Interested parties can access the presentation via webcast, and investors seeking private meetings can arrange them through conference representatives or by contacting the company's investor relations team.

HeartBeam (NASDAQ: BEAT) reported significant progress in Q1 2025, highlighted by successful completion of the VALID-ECG pivotal study showing 93.4% overall diagnostic agreement for arrhythmia assessment. The company submitted a 510(k) application for its 12-lead ECG synthesis software and is having productive FDA discussions. Key developments include:

• Strategic collaboration with AccurKardia to enhance arrhythmia assessment capabilities
• Raised $11.5M through public offering in February 2025
• Added two new US patents, now owning 20 issued patents globally
• Cash position of $8.2M as of March 31, 2025

Financial results showed R&D expenses of $3.5M (vs $2.4M in Q1 2024) and net loss of $5.5M (vs $4.6M in Q1 2024). The company is preparing for commercialization upon FDA clearance and plans to initiate a Pilot Study for ischemia and acute coronary events in H2 2025.

HeartBeam (NASDAQ: BEAT) has secured two new U.S. patents, strengthening its intellectual property portfolio in cardiac monitoring technology. The first patent protects their credit card-sized, cable-free 3D ECG device with chest and finger electrodes that capture high-fidelity electrical signals in three non-coplanar directions. The second patent covers their rhythm analysis algorithm for distinguishing between various heart rhythms using continuous signal input, designed for integration with wearable devices.

The company's 12-lead ECG synthesis software is currently under FDA review, supported by data from the VALID-ECG pivotal study presented at the Heart Rhythm Society conference in April 2025. HeartBeam now holds 20 issued patents worldwide, with 2 allowed patents and 32 pending patents, positioning itself as a leader in cardiac monitoring innovation.

HeartBeam (NASDAQ: BEAT) has appointed CEO Robert Eno to its Board of Directors, expanding from eight to nine members. Eno, who joined as President in January 2023 and became CEO in October 2024, brings over 30 years of medical technology industry experience. The company received FDA clearance for its 3D ECG technology in December 2024 and submitted an FDA application for its 12-lead ECG synthesis software in January 2025.

HeartBeam's technology captures heart electrical signals in 3 non-coplanar directions and synthesizes them into a 12-lead ECG. The company has initiated an Early Access Program to gather feedback on clinical workflow and establish early adopters. Prior to HeartBeam, Eno served as CEO of Preview Medical and held leadership roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular.

HeartBeam (NASDAQ: BEAT) has announced its upcoming first quarter 2025 earnings conference call, scheduled for Tuesday, May 13, 2025, at 4:30 p.m. Eastern time. The call will be hosted by CEO Robert Eno and CFO Timothy Cruickshank, who will discuss Q1 2025 results, regulatory initiatives, commercial-readiness activities, and anticipated milestones. A detailed press release will be issued before the call.

The conference call will include a presentation accessible during the webcast and afterward through the company's investor relations website. A replay will be available for three months until August 13, 2025, through both domestic (1-844-512-2921) and international (1-412-317-6671) dial-in numbers.

HeartBeam has achieved a significant breakthrough in cardiac care technology, announcing successful clinical endpoints in its VALID-ECG pivotal study for its synthesized 12-lead ECG technology. The study, presented at the Heart Rhythm Society's conference in San Diego, demonstrated a 93.4% overall diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment.

The company's innovative solution uses a credit card-sized device featuring patented 3D ECG technology that captures heart electrical signals in 3 non-coplanar directions. These signals are then transformed into a 12-lead ECG using a personalized matrix.

Key highlights:

• FDA application submitted in January 2025 for the 12-lead ECG synthesis software
• Early Access Program launched to gather clinical workflow feedback
• Multicenter trial conducted across 5 major US clinical sites with 198 patients
• Participating institutions include Allegheny Health Network, Mount Sinai Hospital, and Piedmont Heart Institute

The company plans to begin commercialization upon receiving FDA clearance.